December 3rd 2021
Drs. Gupta and Brown discuss a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.
October 21st 2021
Lyudmila Bazhenova, MD, and Frederico Albrecht, MD, consider when to refer to a clinical trial data and how to use real-world evidence when making treatment decisions for patients with EGFR-mutated non–small cell lung cancer based on a recent publication by Bassel Nazha, MD, MPH.
October 15th 2021
Key takeaways from a recent study of tipifarnib as treatment for recurrent and/or metastatic mHRAS head and neck squamous cell carcinoma.
October 8th 2021
Experts collaborate to share and reflect on data from an eNRGy1 global registry study, which analyzed therapy in NRG1 fusion–driven lung cancers.
October 8th 2021
Drs Liliana Bustamante and Richard Kim review “Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases,” and consider how to apply the paper’s findings into clinical practice.
September 13th 2021
Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, provide insight on the results and clinical implications of the EMPIRE-1 trial in prostate cancer.
August 24th 2021
In this program, George Ansstas, MD, and Firas B. Badin, MD, discuss a recently published paper on ctDNA for analysis of immunotherapy efficacy in individual patients with solid tumor malignancies.
August 20th 2021
In this program, D. Ross Camidge, MD, PhD, and Alexander Spira, MD, PhD, discuss a recently published paper on the anti-HER3 monoclonal antibody seribantumab in the treatment of tumor samples with oncogenic NRG1 fusions.
August 9th 2021
In this journal club-like program, Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss a recently published paper about third-line treatments for HER2-positive breast cancer and provide insight about its implications for clinical practice.